164 related articles for article (PubMed ID: 12600184)
1. [Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].
Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Wołowiec D; Kapelko-Słowik K; Kuliczkowski K
Pol Arch Med Wewn; 2002 Sep; 108(3):873-8. PubMed ID: 12600184
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
4. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
Lewis NR; Pallis M; Russell NH
Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.
Lickliter JD; Kratzke RA; Nguyen PL; Niehans GA; Miller JS
Exp Hematol; 1999 Oct; 27(10):1519-27. PubMed ID: 10517493
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.
Aref S; Salama O; Al-Tonbary Y; Mansour A
Hematology; 2004 Apr; 9(2):113-21. PubMed ID: 15203866
[TBL] [Abstract][Full Text] [Related]
8. mRNA expression of variant Fas molecules in acute leukemia cells.
Inaba H; Komada Y; Li QS; Zhang XL; Tanaka S; Azuma E; Yamamoto H; Sakurai M
Am J Hematol; 1999 Nov; 62(3):150-8. PubMed ID: 10539881
[TBL] [Abstract][Full Text] [Related]
9. Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: a clinical analysis.
Wu Q; Chen H; Fang J; Xie W; Hong M; Xia L
Leuk Res; 2012 Mar; 36(3):275-80. PubMed ID: 21917312
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
12. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
15. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients.
Baryshnikov AYu ; Polosukhina ER; Tupitsin NN; Gavrikova NV; Andreeva LYu ; Zabotina TN; Mayakova SA; Kurmashov VI; Syrkin AB; Kadagidze ZG; Blochin DYu ; Shishkin YuV
Adv Exp Med Biol; 1999; 457():251-8. PubMed ID: 10500800
[TBL] [Abstract][Full Text] [Related]
16. [Expression of Fas on monocytes and the level of plasma soluble FasL in patients with chronic renal failure].
Jiang J; Hou F; Liu Z; Liu J; Zhang X
Zhonghua Nei Ke Za Zhi; 2001 Jan; 40(1):25-8. PubMed ID: 11798554
[TBL] [Abstract][Full Text] [Related]
17. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
18. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].
Takeda K; Ohara E; Kaneda T; Hashimoto K; Sasaki M
Rinsho Byori; 1999 Oct; 47(10):961-5. PubMed ID: 10590671
[TBL] [Abstract][Full Text] [Related]
19. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Bremer E; ten Cate B; Samplonius DF; de Leij LF; Helfrich W
Blood; 2006 Apr; 107(7):2863-70. PubMed ID: 16332967
[TBL] [Abstract][Full Text] [Related]
20. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
